NCT03999099View on ClinicalTrials.gov

Targeting Orexin to Treat Nicotine Dependence

PHASE1RecruitingINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions

Nicotine Dependence

Interventions

DRUG

Suvorexant 20 mg

Suvorexant at a high dose (20 mg)

DRUG

Suvorexant 10 mg

Suvorexant at a low dose (10 mg)

DRUG

Placebo oral tablet

Placebo

Trial Locations (1)

02478

RECRUITING

McLean Hospital, Belmont

All Listed Sponsors

lead

Mclean Hospital

OTHER